Cargando…

HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions

Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against post-trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Henere, Carla, Torné, Aureli, Llupià, Anna, Aldea, Marta, Martí, Cristina, Glickman, Ariel, Saco, Adela, Marimon, Lorena, Manzotti, Carolina, Rakislova, Natalia, Ordi, Jaume, del Pino, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230577/
https://www.ncbi.nlm.nih.gov/pubmed/35746495
http://dx.doi.org/10.3390/vaccines10060887
_version_ 1784735095192551424
author Henere, Carla
Torné, Aureli
Llupià, Anna
Aldea, Marta
Martí, Cristina
Glickman, Ariel
Saco, Adela
Marimon, Lorena
Manzotti, Carolina
Rakislova, Natalia
Ordi, Jaume
del Pino, Marta
author_facet Henere, Carla
Torné, Aureli
Llupià, Anna
Aldea, Marta
Martí, Cristina
Glickman, Ariel
Saco, Adela
Marimon, Lorena
Manzotti, Carolina
Rakislova, Natalia
Ordi, Jaume
del Pino, Marta
author_sort Henere, Carla
collection PubMed
description Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against post-treatment HSIL. A second unanswered question is whether the vaccine has any effect in women with persistent HPV after treatment. We aimed to address these questions in a study of 398 women undergoing excisional treatment from July 2016 to December 2019. Vaccination was funded and offered to all women undergoing treatment. A total of 306 women (76.9%) accepted HPV vaccination (vaccinated group): 113 (36.9%) received the first dose before excision and 193 (63.1%) after the procedure. A total of 92 women (23.1%) refused the vaccine (non-vaccinated group). Women vaccinated before treatment showed a lower rate of post-treatment HSIL compared with non-vaccinated women (0.9% vs. 6.5%; p = 0.047). Among women with persistent HPV infection after treatment, those who had received the vaccine showed a lower prevalence of post-treatment HSIL than non-vaccinated women (2.6% vs. 10.5%; p = 0.043). In conclusion, this study shows that HPV vaccination before treatment reduces the prevalence of post-treatment HSIL and suggests that vaccination might even benefit women with persistent HPV after treatment.
format Online
Article
Text
id pubmed-9230577
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92305772022-06-25 HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions Henere, Carla Torné, Aureli Llupià, Anna Aldea, Marta Martí, Cristina Glickman, Ariel Saco, Adela Marimon, Lorena Manzotti, Carolina Rakislova, Natalia Ordi, Jaume del Pino, Marta Vaccines (Basel) Article Several questions regarding the role of vaccination in women treated for high-grade cervical intraepithelial lesion (HSIL) have not been clarified. One of the main queries is whether the time at which the vaccine is administered (before or after treatment) influences the protection against post-treatment HSIL. A second unanswered question is whether the vaccine has any effect in women with persistent HPV after treatment. We aimed to address these questions in a study of 398 women undergoing excisional treatment from July 2016 to December 2019. Vaccination was funded and offered to all women undergoing treatment. A total of 306 women (76.9%) accepted HPV vaccination (vaccinated group): 113 (36.9%) received the first dose before excision and 193 (63.1%) after the procedure. A total of 92 women (23.1%) refused the vaccine (non-vaccinated group). Women vaccinated before treatment showed a lower rate of post-treatment HSIL compared with non-vaccinated women (0.9% vs. 6.5%; p = 0.047). Among women with persistent HPV infection after treatment, those who had received the vaccine showed a lower prevalence of post-treatment HSIL than non-vaccinated women (2.6% vs. 10.5%; p = 0.043). In conclusion, this study shows that HPV vaccination before treatment reduces the prevalence of post-treatment HSIL and suggests that vaccination might even benefit women with persistent HPV after treatment. MDPI 2022-06-01 /pmc/articles/PMC9230577/ /pubmed/35746495 http://dx.doi.org/10.3390/vaccines10060887 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Henere, Carla
Torné, Aureli
Llupià, Anna
Aldea, Marta
Martí, Cristina
Glickman, Ariel
Saco, Adela
Marimon, Lorena
Manzotti, Carolina
Rakislova, Natalia
Ordi, Jaume
del Pino, Marta
HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
title HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
title_full HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
title_fullStr HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
title_full_unstemmed HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
title_short HPV Vaccination in Women with Cervical Intraepithelial Neoplasia Undergoing Excisional Treatment: Insights into Unsolved Questions
title_sort hpv vaccination in women with cervical intraepithelial neoplasia undergoing excisional treatment: insights into unsolved questions
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230577/
https://www.ncbi.nlm.nih.gov/pubmed/35746495
http://dx.doi.org/10.3390/vaccines10060887
work_keys_str_mv AT henerecarla hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT torneaureli hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT llupiaanna hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT aldeamarta hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT marticristina hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT glickmanariel hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT sacoadela hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT marimonlorena hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT manzotticarolina hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT rakislovanatalia hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT ordijaume hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions
AT delpinomarta hpvvaccinationinwomenwithcervicalintraepithelialneoplasiaundergoingexcisionaltreatmentinsightsintounsolvedquestions